Impact of empagliflozin in patients with diabetes and heart failure

详细信息    查看全文

• 作者：David Pham ; MD^a ; Natalia De Albuquerque Rocha ; MD^b ; Darren K. McGuire ; MD ; MHSc^a ; ^c ; Ian J. Neeland ; MD^a ; ^{ian.neeland@utsouthwestern.edu}
• 关键词：Empagliflozin ; Heart failure ; SGLT2 inhibitor ; Type 2 diabetes mellitus
• 刊名：Trends in Cardiovascular Medicine
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：27
• 期：2
• 页码：144-151
• 全文大小：543 K
• 卷排序：27

文摘

Heart failure (HF) is a common disease with increased risk for mortality and morbidity among patients with type 2 diabetes mellitus (T2DM). Optimal glycemic control in this patient population is challenging as many available therapies can potentially exacerbate symptoms of HF. Empagliflozin is one in a novel class of agents, the sodium glucose co-transporter 2 (SGLT2) inhibitors, that lowers blood glucose by increasing urinary glucose excretion and improves glycemic control and lowers body weight and blood pressure. In the recent EMPA-REG OUTCOME trial, empagliflozin was shown to improve cardiovascular outcomes in patients with T2DM and established cardiovascular risk where it reduced HF hospitalizations and cardiovascular death, with a consistent benefit among patients both with and without baseline HF. Here, we review the empagliflozin data on HF outcomes and discuss potential mechanisms for its benefits in HF with a focus on the potentially significant impact that empagliflozin may have on the care of patients with T2DM and HF in the future.